FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979889274> ?p ?o ?g. }

• W2979889274 abstract "Abstract Abstract 2888 Poster Board II-864 Introduction. Lenalidomide is a thalidomide derivative with improved efficacy. Lenalidomide remains active in multiple myeloma (MM) patients despite previous thalidomide treatment. At present, no data are available on the efficacy of thalidomide in patients previously exposed to lenalidomide. The aim of this study is to evaluate the efficacy of the sequential use of these two drugs in relapsed-refractory MM patients. Methods. A total of 118 MM patients received lenalidomide treatment and were categorized as follows: 1) patients with no previous thalidomide exposure (T0) (n=24); 2) thalidomide sensitive patients (TS) (n=20) (at least a PR during thalidomide exposure); 3) thalidomide resistant patients (TR) (n=71) (progressive disease during thalidomide treatment). Ten patients in T0 group received MPR at diagnosis while all other patients received lenalidomide-dexametasone as salvage therapy. Median prior lines of therapy in T0, TS and TR groups was 1 (range 0-3), 2 (range 1-5) and 3 (range 1-6), respectively. Fifteen patients received thalidomide-dexametasone treatment after lenalidomide exposure (12 patients received MPR at diagnosis and 3 patients lenalidomide-dexametasone at relapse). All patients had progressive disease during lenalidomide treatment. Response to treatment was assessed according to IMWG uniform response criteria with the addition of MR. Results. No statistical difference was found in the overall response rate (more than PR) between T0 and TS patients (83.3% vs 65%, p=0.18) and between TS and TR patients (65% vs 61.9%, p=0.8). Treatment with lenalidomide-dexametasone led to a significant improved overall response when compared T0 vs TR patients (83.3% vs 61.9%, p=0.04). Lenalidomide was significantly more effective in prolonging TTP in T0 with respect to TS and TR groups (median TTP not reached, P=0.0001) and also prolonged TTP in TS vs TR patients (median, 11 vs 7,5 months P=0.03). Median OS was not reached in T0 group after 48 months (P=0.09) and was similar in TS and TR groups (median 15 months, P=0.5). In the 15 patients treated with lenalidomide first and then with thalidomide-dexametasone as salvage therapy, response rate was: 27% at least PR, 40% MR, 27% NR, 13% PD. Median TTP was 7 months (range 2-30) and median OS was not reached at 40 months. Conclusion. Lenalidomide is highly effective in MM patients thalidomide resistance. Thalidomide is already effective in MM patients pure resistance to lenalidomide. TTP was similar in both groups (7 months). Clinical efficacy of lenalidomide in relapsed-refractory myeloma patients already exposed to thalidomide is similar to the efficacy of thalidomide in patients already exposed to lenalidomide. Disclosures: Guglielmelli: Janssen Cilag: Honoraria; Celgene: Honoraria. Bringhen:Janssen Cilag: Honoraria; Celgene: Honoraria. Cavallo:Celgene: Honoraria. Petrucci:Celgene: Honoraria; Janssen Cilag: Honoraria. Caravita:Celgene: Honoraria; Janssen Cilag: Honoraria. Offidani:Celgene: Honoraria; Janssen Cilag: Honoraria. Corradini:Celgene: Honoraria; Janssen Cilag: Honoraria. Boccadoro:Janssen Cilag: Honoraria; Celgene: Honoraria; Novartis: Honoraria. Saglio:Celgene: Honoraria; Novartis: Honoraria; Bristol Myers: Honoraria. Palumbo:Celgene: Honoraria; Janssen Cilag: Honoraria." @default.
• W2979889274 created "2019-10-18" @default.
• W2979889274 creator A5017455719 @default.
• W2979889274 creator A5017728103 @default.
• W2979889274 creator A5018139001 @default.
• W2979889274 creator A5019949455 @default.
• W2979889274 creator A5034587847 @default.
• W2979889274 creator A5042005810 @default.
• W2979889274 creator A5045814742 @default.
• W2979889274 creator A5050426287 @default.
• W2979889274 creator A5053560614 @default.
• W2979889274 creator A5059967673 @default.
• W2979889274 creator A5067110512 @default.
• W2979889274 creator A5068769311 @default.
• W2979889274 creator A5077328355 @default.
• W2979889274 creator A5083644983 @default.
• W2979889274 date "2009-11-20" @default.
• W2979889274 modified "2023-09-30" @default.
• W2979889274 title "Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients." @default.
• W2979889274 doi "https://doi.org/10.1182/blood.v114.22.2888.2888" @default.
• W2979889274 hasPublicationYear "2009" @default.
• W2979889274 type Work @default.
• W2979889274 sameAs 2979889274 @default.
• W2979889274 citedByCount "2" @default.
• W2979889274 crossrefType "journal-article" @default.
• W2979889274 hasAuthorship W2979889274A5017455719 @default.
• W2979889274 hasAuthorship W2979889274A5017728103 @default.
• W2979889274 hasAuthorship W2979889274A5018139001 @default.
• W2979889274 hasAuthorship W2979889274A5019949455 @default.
• W2979889274 hasAuthorship W2979889274A5034587847 @default.
• W2979889274 hasAuthorship W2979889274A5042005810 @default.
• W2979889274 hasAuthorship W2979889274A5045814742 @default.
• W2979889274 hasAuthorship W2979889274A5050426287 @default.
• W2979889274 hasAuthorship W2979889274A5053560614 @default.
• W2979889274 hasAuthorship W2979889274A5059967673 @default.
• W2979889274 hasAuthorship W2979889274A5067110512 @default.
• W2979889274 hasAuthorship W2979889274A5068769311 @default.
• W2979889274 hasAuthorship W2979889274A5077328355 @default.
• W2979889274 hasAuthorship W2979889274A5083644983 @default.
• W2979889274 hasConcept C121332964 @default.
• W2979889274 hasConcept C126322002 @default.
• W2979889274 hasConcept C141071460 @default.
• W2979889274 hasConcept C142424586 @default.
• W2979889274 hasConcept C143998085 @default.
• W2979889274 hasConcept C2776063141 @default.
• W2979889274 hasConcept C2776364478 @default.
• W2979889274 hasConcept C2776694085 @default.
• W2979889274 hasConcept C2779609412 @default.
• W2979889274 hasConcept C2780775027 @default.
• W2979889274 hasConcept C71924100 @default.
• W2979889274 hasConcept C87355193 @default.
• W2979889274 hasConcept C90924648 @default.
• W2979889274 hasConceptScore W2979889274C121332964 @default.
• W2979889274 hasConceptScore W2979889274C126322002 @default.
• W2979889274 hasConceptScore W2979889274C141071460 @default.
• W2979889274 hasConceptScore W2979889274C142424586 @default.
• W2979889274 hasConceptScore W2979889274C143998085 @default.
• W2979889274 hasConceptScore W2979889274C2776063141 @default.
• W2979889274 hasConceptScore W2979889274C2776364478 @default.
• W2979889274 hasConceptScore W2979889274C2776694085 @default.
• W2979889274 hasConceptScore W2979889274C2779609412 @default.
• W2979889274 hasConceptScore W2979889274C2780775027 @default.
• W2979889274 hasConceptScore W2979889274C71924100 @default.
• W2979889274 hasConceptScore W2979889274C87355193 @default.
• W2979889274 hasConceptScore W2979889274C90924648 @default.
• W2979889274 hasLocation W29798892741 @default.
• W2979889274 hasOpenAccess W2979889274 @default.
• W2979889274 hasPrimaryLocation W29798892741 @default.
• W2979889274 hasRelatedWork W2474872853 @default.
• W2979889274 hasRelatedWork W2525909300 @default.
• W2979889274 hasRelatedWork W2525940099 @default.
• W2979889274 hasRelatedWork W2549070662 @default.
• W2979889274 hasRelatedWork W2556510606 @default.
• W2979889274 hasRelatedWork W2563223569 @default.
• W2979889274 hasRelatedWork W2583767632 @default.
• W2979889274 hasRelatedWork W2588197073 @default.
• W2979889274 hasRelatedWork W2595611953 @default.
• W2979889274 hasRelatedWork W2744601260 @default.
• W2979889274 hasRelatedWork W2759274067 @default.
• W2979889274 hasRelatedWork W2921343130 @default.
• W2979889274 hasRelatedWork W2978647547 @default.
• W2979889274 hasRelatedWork W2979577217 @default.
• W2979889274 hasRelatedWork W2979605175 @default.
• W2979889274 hasRelatedWork W2980027503 @default.
• W2979889274 hasRelatedWork W2980101559 @default.
• W2979889274 hasRelatedWork W2984791646 @default.
• W2979889274 hasRelatedWork W3015486851 @default.
• W2979889274 hasRelatedWork W3110392978 @default.
• W2979889274 isParatext "false" @default.
• W2979889274 isRetracted "false" @default.
• W2979889274 magId "2979889274" @default.
• W2979889274 workType "article" @default.